New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
21:13 EDTTSROTESARO announces final results from three Phase 3 trials of rolapitant
TESARO announced that final results from three Phase 3 trials of rolapitant, an investigational neurokinin-1 receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting, were presented at the American Society of Clinical Oncology, ASCO, annual meeting in Chicago. "We are very pleased with these pivotal data which, along with the previously conducted Phase 2 study, will form the basis of our New Drug Application submission to the U.S. Food and Drug Administration in mid-2014," said Mary Lynne Hedley, Ph.D., president of TESARO. "Additionally, we look forward to expanding our niraparib development program to include clinical trials in the small cell lung cancer and first line ovarian cancer settings."
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:51 EDTTSROTESARO, Myriad Genetics announce companion diagnostics collaboration
Subscribe for More Information
November 19, 2014
07:09 EDTTSROJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 12, 2014
11:17 EDTTSROLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 11, 2014
15:43 EDTTSROLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use